[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The University of Hong Kong-Shenzhen Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":84},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,38,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100593978","international-collaborative-study-on-ajccuicc-tnm-10-for-nasopharyngeal-cancer-100593978",false,"NCT07013461","International Collaborative Study on AJCC\u002FUICC TNM-10 for Nasopharyngeal Cancer","International Collaborative Study to Develop the AJCC\u002FUICC TNM Version-Ten for Nasopharyngeal Cancer","Inclusion Criteria:\n\n* All histologically confirmed nasopharyngeal carcinoma treated between 1 Oct 2025 and 30 Sep 2026\n\nExclusion Criteria:\n\n* Non-epithelial tumors of nasopharynx (including lymphoma, sarcoma of soft tissue, bone\u002Fcartilagetumors. mucosal melanoma, salivary type tumors)","ALL","18 Years",{"count":19,"type":20},5000,"ESTIMATED","OBSERVATIONAL","The goal of this international, multicenter, prospective observational study is to improve prognostication and prediction of failure pattern for nasopharyngeal carcinoma (NPC), in order to provide more accurate guidance for personalized treatment decision. Firstly, we aim to improve the fundamental TNM staging system \\[The American Joint Committee on Cancer(AJCC)\u002FUnion for International Cancer Control(UICC) TNM Version-Nine\\] based on universally assessable anatomical parameters. Secondly, we aim to further refine prognostication for individual patients by integrating anatomical TNM parameters with non-anatomical factors and molecular biomarkers. In addition to the core group of participating centers from China (including Hong Kong) where NPC is most prevalent, the study will enrol patients from multiple countries\u002Fregions including those from non-endemic areas to provide global data. Patients treated with contemplary treatment methods during October 2025 to September 2026 will be recruited and they will be followed up for 5 years to generate detailed records for robust evaluation.\n\nKey Questions:\n\n* To achieve optimal improvement of anatomically based AJCC\u002FUICC TNM Classification for global application\n* To achieve precise prediction of failure pattern for individual patients by integration of TNM system and non-anatomical prognostic factors\u002Fmolecular biomarkers Recruited patients with confirmed histological diagnosis of NPC will undergo standard clinical evaluations and receive treatment per institutional guidelines.\n\nThe anatomical extent of disease at presentation will be evaluated by experienced radiologists and oncologists. The patient will be followed up for 5 years and clinical outcome will be recorded for analyses on correlation with prognostic factors.\n\nThis study will be another important milestone for NPC staging because firstly, this is the first time that the data are based on prospective data to ensure comprehensive coverage of all essential evidence; and secondly, this is the first time that centers from non-endemic countries\u002Fregions will also participate to ensure that the final recommendations are globally applicable. The findings will provide valuable evidence for the development of the AJCC\u002FUICC TNM Version-Ten staging system and prognostic system to improve risk stratification for designing personalized treatment strategy, ultimately leading to improvement of patient outcome and patient selection for future research worldwide.",[24],"Nasopharyngeal Cancinoma (NPC)","RECRUITING","2026-04-28",{"date":28,"type":29},"2026-05-04","ACTUAL",{"date":31,"type":29},"2026-01-09",{"date":33,"type":20},"2031-12-31",{"name":35,"class":36},"The University of Hong Kong-Shenzhen Hospital","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100540226","phase-2-individualized-neoantigen-therapy-with-unusual-radiotherapy-enhancement-inature-100540226","NCT06314087","Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE)","Individualized Tumor Neoantigen Peptide Vaccine in Combination with Unusual Immune Stimulating Radiotherapy in Refractory Solid Tumors (iNATURE) - a Phase II Randomized and Crossover Study","Inclusion Criteria:\n\n1. male or female\n2. age\\>18 years old\n3. with advanced or recurrent malignancies diagnosed by pathology and imaging, who have failed systemic standard therapy or disease progression prior to enrollment and have no effective first-line therapy (for effective therapy, refer to the latest version of the treatment guidelines published by the Chinese Society of Clinical Oncology)\n4. have at least one imaging measurable lesion\n5. with an expected survival of ≥ 3 months\n6. with an ECOG (Eastern Cooperative Oncology Group) score of 0-2\n7. have access to sufficient tumor DNA (circulating tumor DNA or tissue samples) for analysis, or have genomic\u002Fexonic\u002Ftranscriptional data from tumor and normal tissues and the data meet the analysis requirements, qualified for tumor neoantigen screening, or have prepared neoantigen peptides from a certified company (GMP)\n8. women of childbearing age should have negative pregnancy tests within 7 days prior to enrollment, and have no short-term plans to have children and are willing to take protective measures (contraception or other birth control methods) before and during the clinical trial\n9. compliant patients who is and able to follow the study protocol and the follow-up procedures\n\nExclusion Criteria:\n\n1. No neoantigens detected in the sequencing data.\n2. with a history of bone marrow or stem cell transplantation\n3. enrolled in other therapeutic clinical trials; clinical trials of Chinese medicine\n4. with active bacterial or fungal infections\n5. with active HIV (human immunodeficiency virus, human immunodeficiency virus), HCV (hepatitis C virus), HBV (hepatitis B virus), or the herpes virus (except for crusting for more than 4 weeks), or with respiratory viral infections (except for those who have been cured for more than 4 weeks)\n6. with asthma, autoimmune disease, immunodeficiency\n7. under treatment with immunosuppressive drugs\n8. with severe coronary or cerebrovascular disease, or other conditions that concerns the investigator for enrollment\n9. have clinical, psychological or social factors affecting informed consent or study implementation\n10. have a history of drug or peptide allergy, or allergy to other potential immunotherapies\n11. no decision making capacity for civil conduct","80 Years",{"count":47,"type":20},154,"INTERVENTIONAL",[50],"PHASE2","In this study, the investigators provide an individualized tumor neoantigen peptide vaccine in combination with radiotherapy to patients with advanced malignant solid tumors. The investigators observe the post-treatment tumor burden status, the immune response induced by immune preparations, and the prolongation of patient survival time, aiming to evaluate the effectiveness and safety of the individualized tumor neoantigen peptide vaccine in combination with radiotherapy",[53],"Advanced Tumors",[55],"Neoantigen Peptide Vaccines","2025-03-19",{"date":58,"type":29},"2025-03-25",{"date":60,"type":29},"2024-01-31",{"date":62,"type":20},"2026-08-31",{"name":35,"class":36},2,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":37},"100561673","non-invasive-filling-pressurenifp-device-based-on-low-frequency-heart-sound-in-assessment-of-congestion-in-heart-failure-patients-100561673","NCT06593223","Non-invasive Filling Pressure(NIFP) Device Based on Low Frequency Heart Sound in Assessment of Congestion in Heart Failure Patients","Inclusion Criteria:\n\n* Acute heart failure；Stabilized outpatient chronic heart failure patients；Willing to sign the inform consent\n\nExclusion Criteria:\n\n* 1.Patients under 18 years old 2.Patients with congenital heart diseases (e.g., tetralogy of Fallot, atrial septal defect, Fontan disease, single chamber disease) 3.Patients with implanted artificial mechanical valves, pacemaker or ICD. 4.Patients with significant back issues that prevent them from lying supine on the bed 5.Pregnant patients 6.Patient wight under 35 kg or over 150 kg 7.Patients who are attaching to other medical device that prevent them to receive a test by the study device.",{"count":72,"type":20},400,"Congestion plays a key role in heart failure (HF) trajectory .Clinical congestion refers to the signs and symptoms resulting from elevated cardiac filling pressures. Hemodynamic congestion refers to elevated cardiac filling pressures, which may occur days or weeks before the presentation of symptoms , , .\n\nSerial assessment of congestion is required in each encounter of the HF patients, while in current clinical practice, serial assessment of congestion relies on physical examination, sometimes supported by BNP test. Both physical and BNP test are reported to be unreliable in some cases ， . Echocardiography is good tool, but it requires skilled physician to operation and is more time consuming. In general, there is unmet needs of better tools for serial assessment of congestion in HF patient management.\n\nIn this study, we aim to prospectively observe and evaluate the feasibility of using a novel non-invasive device in assessment of congestion in HF patients.",[75],"Heart Failure","2024-09-09",{"date":78,"type":29},"2024-09-19",{"date":80,"type":29},"2022-07-01",{"date":82,"type":20},"2025-07-01",{"name":35,"class":36},""]